Returning as Europe’s longest-standing and definitive ADC forum, the 16th World ADC London is the week for anyone working in ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

In a landscape where access is no longer an after-thought, but a strategic imperative, this summit tackles the full lifecycle ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

Thermo Fisher Scientific has agreed to acquire Clario Holdings for nearly $8.9 billion, in a deal that would give it control ...

And this is where targeted radiotherapeutics come in. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr ...

Inizio brings in seasoned pharma exec for top job. A new chapter begins at Inizio with the appointment of Ryan Quigley as CEO ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...